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Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized
and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are
lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity
(OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices.
Methods
and results
Authors of studies publishedbefore January2015, reporting associations between platelet reactivity, ST, andmajor bleed-
ing were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet func-
tion assays. Based on best available evidence for each device (exploratory studies), LPR–OPR–HPR categories were
defined as ,95, 95–208, and .208 PRU for VerifyNow, ,19, 19–46, and .46 U for the Multiplate analyser and
,16, 16–50, and .50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97%
were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio
(RR) and 95% CI: 2.73 (2.03–3.69), P, 0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71–0.99), P ¼ 0.04] com-
pared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47–2.06),
P, 0.00001], without any further benefit in ST [RR: 1.06 (0.68–1.65), P ¼ 0.78] in contrast to OPR. Mortality was sig-
nificantly higher in patients with HPR compared with other categories (P, 0.05). Validation cohorts (n ¼ 14) confirmed
all results of exploratory studies (n ¼ 3).
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Conclusions Platelet reactivity assessmentduring thienopyridine-type P2Y12-inhibitors identifies PCI-treatedpatients athigher risk for
mortality and ST (HPR) or at an elevated risk for bleeding (LPR).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords P2Y12-inhibitors † Platelet reactivity † Stent thrombosis, Bleeding
Introduction
Dual antiplatelet treatment (DAPT) consisting of aspirin and a
P2Y12-inhibitor is recommended in patients undergoing percutan-
eous coronary interventions (PCIs) to prevent thrombotic complica-
tions.1 However, adjunctive administration of all currently available
P2Y12-inhibitors has been associated with an increased risk for
bleeding.2 – 4 Since both ischaemic and bleeding events are important
correlates of overall patient survival, attempts minimizing both com-
plications in PCI-treated patients are highly warranted.5 Monitoring
platelet reactivity during P2Y12-inhibitors was hoped to help
prevent bleeding and/or stent thrombosis (ST) as numerous prior
studies have linked high platelet reactivity (HPR) to a greater risk
for ischaemic complications, while low platelet reactivity (LPR) has
been associated with greater bleeding events.6,7 However, the pub-
lished cut-offs for HPR and LPR are highly heterogeneous, usually
non-validated outside of the exploratory studies, leading to contro-
versies on the prognostic relevance of platelet function testing in
patients undergoing PCI. Such methodical uncertainties might be—
in part—the reasons for failures of two randomized studies8,9 evalu-
ating the impact of platelet function testing guidance of antiplatelet
therapy.
In the setting of a collaborative analysis, we sought to analyse the
data from a large number of published studies to determine the prog-
nostic impact of platelet reactivity, classified as low (LPR), optimal
(OPR), or high (HPR) by applying standard cut-off criteria in patients
treated with P2Y12-inhibitors.
Methods
Study selection and literature search
For this collaborative analysis, we identified published studies reporting
the rates of major (or clinically relevant) bleeding, mortality, and ST
according to different levels of platelet reactivity in PCI-treated patients.
In line with the recommendations of two prior consensus papers, only
studies using standardized platelet function assays, such as the VerifyNow
P2Y12 assay, the Multiplate analyser with ADP test, or the VASP assay,
were included.6,7 Weconducted a PubMed database search for published
articles until January 2015 using the following pre-defined search terms
alone or in combination: platelet reactivity, clopidogrel, ticagrelor, prasu-
grel, VerifyNow, Multiplate,VASP, ST, and bleeding.Abstracts frommajor
scientific meetings and reference lists of published reviews were also
checked to identify relevant studies. Authors of selected studies were
contacted for collaboration, and after a positive response, original data
were provided by responsible authors for all analyses (Figure 1).
Eligibility criteria and data extraction
We restrictedouranalysis to studies that met all of the following inclusion
criteria: (i) patients with stable or acute coronary artery disease undergo-
ing PCI with an assessment of platelet reactivity during or in close
proximity (≤30 days) to the performed intervention; (ii) patients receiv-
ing aspirin and a P2Y12-receptor inhibitor for PCI; (iii) assessment of
platelet function with the VerifyNow, Multiplate analyser, or VASP
assay; and (iv) reporting clinical outcomes in relation to platelet reactivity
findings including ST, major or clinically relevant bleeding, and mortality.
Exclusion criteria included application of less widely available or
non-standardized assays for platelet function testing (e.g. light transmis-
sion aggregometry), studies using other types of antiplatelet agents
(e.g. cilostazol, vorapaxar). In addition, studies primarily conducted in
non-Western patients were also excluded due to the hypothesized dif-
ferences in the pharmacodynamic response to P2Y12-inhibitors across
races, also referred to as the ‘East-Asian paradox’.10 The authors
agreed that the cut-offs identified by exploratory studies (defined
below) might not be applicable to the non-Western population given
the low number of such ancestry in these cohorts. In studies where
parallel results with different platelet function assays were presented
in the same cohort, the assay with the largest numbers of tested indivi-
duals was used for the analysis to prevent over-representation of the
studies in the analysis.
Platelet reactivity assessment and cut-off
values
To test the prognostic relevance of platelet reactivity classified as low
(LPR), optimal (OPR), or high (HPR), we used the best available evidence
to identify cut-off values for the included platelet function assays. The
chosen cut-off values were in line with recent recommendations of
two expert opinion papers,6,7 except for the LPR cut-off of the Verify-
Now assay which was based on results of the large ADAPT-DES registry
that was not available at the time of the consensus papers.11 Therefore,
the selected cut-off values for LPR, OPR, and HPR categories were
,95, 95–208, and .208 PRU for VerifyNow,11,12 ,19, 19–46, and
.46 U for the Multiplate analyser,13,14 and ,16, 16–50, and .50%
for VASP15 assays, respectively.
Clinical endpoint definitions and subgroups
Definite orprobable STwasdefined according to theAcademicResearch
Consortium (ARC) criteria. Clinically relevant major bleeding complica-
tions were recorded with the definition used in each study. Accepted
bleeding scales included TIMI major, BARC type ≥ 2, and ADAPT-
defined clinically relevant bleeding. When rates of major bleeding were
not available, the combined rate of major and minor events was used in
the analysis. All-cause mortality was used if available; otherwise cardio-
vascular mortality was substituted. Outcomes were analysed for the
longest follow-up period available within each study. Pre-specified sub-
group analyses were planned for different platelet function assays, ACS
vs. non-ACS patients, prasugrel/ticagrelor vs. clopidogrel treatment,
and exploratory vs. validation trials.
Statistical analysis
For this collaborative analysis, responsible authors were contacted
individually to provide the rate of ST, bleeding, and mortality according
to the standardized cut-off values for LPR, OPR, and HPR groups in
their specific cohorts. Using the obtained dataset, we performed a
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weighted fixed-effect meta-analysis using the Mantel–Haenszel method
to compare the relative risk (risk ratio, RR) of outcome events in the HPR
and LPR groups in contrast to patients with OPR, used as reference. Sen-
sitivity analyses were performed in all outcomes with random-effect
modelling. When risks of bleeding and ST were compared according to
platelet reactivity categories in the same plot, absolute risk estimates
were preferred rather than RR to demonstrate the clinical relevance of
the trade-off between ST and bleeding. Therefore, fixed-effect
Mantel–Haenszel weighted risk differences (RDs) were calculated with
the OPR group as reference. To further corroborate our statistical find-
ings, unweighted analyses were performed to obtain RR from pooled
crude event rates. Consistency of the obtained results was analysed in
pre-defined subgroups by interaction testing. A two-sided P-value of
,0.05 was considered statistically significant in all comparisons. Statistic-
al analyses were performed with Review Manager (RevMan) computer
program version 5.1 (Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2011.) and the Comprehensive Meta-analysis
software version 2 (Biostat, Englewood, NJ, USA).
Results
Study cohorts
Overall, 17 studies9,12,13,15– 28 with 20 839 patients were identified
and included in the analysis (Figure 1). Median follow-up time was
8.5 months (minimum–maximum: 1–17). Baseline characteristics
and clinical results of the included studies are summarized in
Table 1. All studies reported definite/probable ST according to the
ARC criteria. Thirteen of the 17 studies reported bleeding events
according to the TIMI scale, two studies22,28 used the BARC defin-
ition, one study reported moderate/several events on the GUSTO
scale,9 and one study used an own bleeding definition (ADAPT-
DES)12 for clinically relevant bleeding (Table 1). In total, data were
available for 13 377 patients with the VerifyNow device, for 3908
patients with the Multiplate analyser, and for 3554 patients with
the VASP assay. The vast majority of patients (97%) was treated
with clopidogrel and only 3% received prasugrel. No eligible study
was identified in patients on ticagrelor.
Outcome data
By applying standard cut-off values, 41% (n ¼ 8554) of the patients
had HPR, 20% (n ¼ 4073) LPR, and 39% (n ¼ 8212) OPR. Patients
with HPR demonstrated a significantly higher risk for ST compared
with those with OPR (2.73, 95% CI: 2.03–3.69, P, 0.00001,
Figure 2, Supplementary material online, Figure S1), while the risk of
ST did not further differ between patients with LPR and OPR (RR:
1.06, 95% CI: 0.68–1.65, P ¼ 0.78, Figure 2, Supplementary material
online, Figure S2) Unweighted analyses were consistent with these
findings (Figure 2). Regarding bleeding, patients with HPR showed a
slight decrease compared with those with OPR (RR: 0.84, 95% CI:
0.71–0.99, P ¼ 0.04), but patients with LPR had a significant,
1.7-fold higher risk in comparison to those with OPR (RR: 1.74,
Figure 1 Flowchart of study selection. LTA, light transmission aggregometry.
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Table 1 Baseline characteristics of the 17 studies included in the collaborative analysis
First author Acronym Year n Expl
study
Device P2Y12-inhibitor Definition of
bleeding
HPR
(%)
LPR
(%)
Age
(mean)
Female
gender
(%)
DM
(%)
ACS
(%)
DES
(%)
Median length
of follow-up
(months)
Bonello15 – 2012 301 Yes VASP Prasugrel TIMI major 25.2 27.9 68 11 23 100 53 12
Breet19 POPular 2010 1052 No VerifyNow Clopidogrel TIMI major 53.3 7.8 64 25 18 0 64 12
Campo20 – 2011 300 No VerifyNow Clopidogrel TIMI major + minor 20.7 27.0 66 23 24 61 71 17
Cuisset22 POBA 2013 1542 No VASP Clopidogrel,
prasugrel
BARC type ≥ 2 30.0 8.5 64 20 30 100 58 6
Freynhofer17 WILMAA 2011 300 No VASP Clopidogrel TIMI major 75.0 3.3 62 32 27 64 65 7
Mangiacapra23 ARMYDA-PROVE 2012 732 No VerifyNow Clopidogrel TIMI major 48.1 7.1 66 27 30 0 27 1
Marcucci27 – 2009 683 No VerifyNow Clopidogrel TIMI major 45.1 15.8 69 24 26 100 18 12
Morel24 – 2011 433 No VASP Clopidogrel TIMI major 6.9 57.3 65 25 37 76 45 9
Patti26 ARMYDA-PRO 2008 160 No VerifyNow Clopidogrel TIMI major 59.4 4.4 66 19 34 54 26 1
Patti25 ARMYDA-BLEEDING 2011 310 No VerifyNow Clopidogrel TIMI major 59.4 4.2 67 22 37 32 25 1
Palmerini28 GEPRESS 2014 978 No VASP Clopidogrel BARC type ≥2 48.9 7.7 67 24 27 100 59 12
Price9 GRAVITAS 2011 1692a No VerifyNow Clopidogrel GUSTO mod/severe 70.0 8.0 63 30 41 15 100 5.7
Sibbing13 ISAR 2010 2533 Yes Multiplate Clopidogrel TIMI major 16.9 38.5 68 24 29 12 100 1
Sibbing21 ISAR-REACT 4 2012 564 No Multiplate Clopidogrel TIMI major 36.3 27.0 68 22 31 100 100 1
Siller-Matula18 MADONNA 2012 395a No Multiplate Clopidogrel TIMI major 36.2 28.4 64 24 34 37 91 1
Siller-Matula16 PEGASUS PCI 2012 416 No Multiplate Clopidogrel TIMI major 36.3 28.6 64 24 32 34 99 12
Stone12 ADAPT-DES 2013 8,448 Yes VerifyNow Clopidogrel ADAPT-defined 42.7 20.0 64 26 32 52 100 12
ACS, acute coronary syndrome; DES, drug-eluting stent; DM: diabetes, Expl, exploratory studies that formed the basis of the standardized cut-off definitions; HPR, high platelet reactivity; LPR, low platelet reactivity.
aOnly patients on 75 mg clopidogrel without adjustment included from these studies.
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95% CI: 1.47–2.06, P, 0.00001, Figure 3, Supplementary material
online, Figures S3 and S4) Unweighted analyses confirmed the
higher risk of bleeding in the LPR group; however, the risk of bleeding
did not differ between patients with HPR and OPR (Figure 3). In case
of mortality, patients with HPR had a significantly higher risk
compared with patients with OPR (HR: 1.54, 95% CI: 1.22–1.94,
P ¼ 0.0002) or LPR (HR: 1.45, 95% CI: 1.04–2.02, P ¼ 0.03,
Figure 4, Supplementary material online, Figures S5 and S6).
Outcome data: rationale for the ‘optimal’
range of platelet reactivity
Sincebleedingevents were3.4-foldmore frequent thanST (total: 797
vs. 236 events) during the mean follow-up of 8.5 months, absolute
RDs were used to better capture the trade-offs in bleeding and ST
between various platelet reactivity groups (Figure 5). When platelet
reactivity levels were grouped only as low or high, the results sug-
gested that a significant reduction in ST in the non-HPR group may
only be achieved at the price of a large increase in bleeding, and vice
versa, lower risk for bleeding in the non-LPR group was associated
with an excess risk of ST (Figure 5A). However, when an ‘optimal’
range of platelet reactivity (OPR) was introduced and used as a refer-
ence, a large reduction in bleedingwasobserved in this group without
any excess in ST compared with LPR (Figure 5B). Similarly, the OPR
group had a significantly lower risk for ST, with only a slight absolute
increase in bleeding compared with patients with HPR (Figure 5B).
Subgroup and sensitivity analyses
Based on interaction analyses, the impact of HPR on ST was consist-
ent in all subgroups (Figure 6). The predicted risk of bleeding was also
directionally similar for LPR in the tested subgroups; however, signifi-
cant interactions for even stronger associations were observed in
some subgroups (Figure 6). Random-effects modelling demonstrated
similar results to fixed-effect analyses for all outcomes (Supplemen-
tary material online, Table S1).
Figure 2 Relative risk of stent thrombosis according to platelet reactivity levels. RR, risk ratio.
Figure 3 Relative risk of bleeding events according to platelet reactivity levels. RR, risk ratio.
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Discussion
This collaborative analysis represents the first attempt towards clin-
ical validation of standardized cut-off points for platelet function
testing in a large sample of patients undergoing PCI. Main results
can be summarized as follows:
(i) Thienopyridine-treated patients with HPR have a 2.7-fold
higher risk for ST and a 1.5-fold higher risk for mortality com-
pared with those with OPR following PCI.
(ii) Patients with LPR show a 1.7-fold higher risk for major bleeding
complications without any further reduction in the risk of ST
compared to patients with OPR.
(iii) These results suggest the existence of an optimal range of
P2Y12-inhibition (OPR) that can be considered as a therapeutic
window, within which the predicted risk of ST and major bleed-
ing is the lowest after PCI.
Finding the balance between efficacy and safety for patients treated
with P2Y12-inhibitors is a key aspect to improve prognosis in patients
after PCI. Despite demonstrated reductions in ischaemic complica-
tions (including ST) with currently available P2Y12-inhibitors among
patients undergoing PCI, the price to pay has always been a higher
risk for bleeding.2– 4 Prior analyses have confirmed that the higher
the level of P2Y12-inhibition, the lower the rate of thrombotic
events29; however, an inverse association exists for bleeding.3,4
Moreover, active metabolite generation and platelet reactivity inhib-
ition of available thienopyridine-type P2Y12-inhibitors are highly vari-
able between patients, affected by common genetic variants and
clinical factors that further complicate accurate risk assessment and
Figure 4 Relative risk of mortality according to platelet reactivity levels. RR, risk ratio.
Figure 5 Absolute risk of stent thrombosis and bleeding according to platelet reactivity levels. (A) Risk estimates when platelet reactivity is cate-
gorized into groups of low platelet reactivity or high platelet reactivity. (B) A comparison of platelet reactivity categorized as low, optimal, or high. ST,
stent thrombosis.
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selectionof theoptimal P2Y12-inihbitor for the individual.
7 Risk strati-
fication by clinical scores is often flawed by the fact that most of the
used risk markers for thrombotic complications are also predictors
of bleeding events (such as age, hypertension, or renal failure). There-
fore, clinical scores might help to predict bleeding and thrombosis,
but have limited usefulness in balancing such complications in clinical
practice because they do not well discriminate between the two un-
wanted outcomes. With this respect, measuring residual platelet re-
activity during P2Y12-inhibitor treatment was suggested as a valuable
option to help stratifying patients according to bleeding and throm-
bosis, as several observational studies have linked HPR to higher
risk for ST and LPR to increased risk for bleeding.12,14,15
Despite these promising observations, major drawbacks to-
wards recommending platelet function testing for risk assessment
after PCI were the large methodical heterogeneity in assessing
on-treatment platelet reactivity and lack of generally applicable
cut-off values to define patients with HPR and LPR. In addition, it
was also unclear how the two extreme platelet reactivity categories
are related to an intermediate range of platelet inhibition, hypothe-
sized as ‘optimal’ (OPR).14 In spite of these limitations, two recent
expert consensus papers6,7 proposed specific cut-off values to
define HPR and LPR, acknowledging; however, the preliminary
nature of these values and lack of proper validation in sufficient
studies.
Therefore, the present collaborative analysis represents an im-
portant step forward in defining standard cut-off points for selected
platelet function assays and validating them in a large population of
patients undergoing PCI. Based on our results, the proposed and
herein tested cut-off values were highly significantly (P, 0.00001)
associated with ST (46 U for Multiplate, 208 PRU for VerifyNow,
and 50% PRI for VASP) and bleeding (19 U for Multiplate, 95 PRU
for VerifyNow, and 16% for VASP). According to the observed
pattern of risk for bleeding and ST, patients in the OPR range had
the lowest net rates of adverse events, enabling a unique and sharp
discrimination of bleeding and ischaemia bya single biomarker assess-
ment (Figure 5B). Interestingly, the more traditional view of platelet
reactivity, categorizing it as only low (LPR) or high (HPR), suggested
that the risk of bleeding and ST is complementary; i.e. a decreased
risk in one side is always accompanied by a significant increase on
the other (Figure 5A). This paradigm may be challenged by introducing
Figure 6 Interaction analysis according to pre-defined subgroups. ACS, acute coronary syndrome; HPR, high platelet reactivity; LPR, low platelet
reactivity.
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the group of OPR, where a significant reduction in bleeding was
observed without an excess risk in ST compared with LPR, and
also, a significant reduction in ST was observed with only a minor,
even doubtful (see Figure 3) increase in bleeding in contrast to HPR.
Importantly, interaction testing confirmed that our findings might
be relevant in several subgroups: most importantly, validation
cohorts corroborated the selection of cut-off points for HPR and
LPR based on exploratory trials (Figure 6). Based on the interaction
analyses for bleeding, some subgroups showed even stronger
associations between LPR and bleeding; however, we believe these
differences should be viewed and interpreted carefully given the
heterogeneity of patients included in various subgroups.
It is important to highlight that despite the potential value of
platelet reactivity to stratify patients into categories of risk for
bleeding and ST, the clinical benefits of adjusting platelet reactivity
based on monitoring treatment, by targeting the optimal range
considered as a therapeutic window is still unknown, and cannot
be answered on the basis of our analysis. In this regard, prior rando-
mized clinical trials (GRAVITAS, TRIGGER-PCI, and ARCTIC)8,9,30
using the VerifyNow assay were disappointing due to lack of
clinical improvements after treatment adjustments based on plate-
let function testing. However, none of these studies targeted an
optimal range of platelet reactivity, were characterized by no9 or
only minimal utilization8 of potent antiplatelet agents, focused
mainly on stable coronary artery disease patients30 and were under-
powered.31 Additionally, the two large, completed randomized
trials used cut-off values different from those proposed and
validated in our analysis.8,9 Thus, the concept of tailored antiplatelet
treatment and its possible benefits remains unproven but cannot
be deemed disproved based on these trials.8,9,30 Future studies
(NCT01959451, NCT01538446) are therefore required, using
the validated cut-off values, focusing on high-risk cohorts of patients
and implementing the therapeutic window concept of platelet in-
hibition to assess the clinical relevance of tailored P2Y12-inhibition
therapy.
Although our analysis provides new evidence in a large sample of
patients by validating cut-off points for risk stratification, we are
aware of limitations. First, we were unable to perform adjusted Cox-
proportional hazard analyses based on individual time-dependent
data. This limitation does not influence our conclusions regarding
the prognostic importance of platelet reactivity for risk assessment.
Although adjusted analyses are useful to understand whether the
associations between platelet reactivity values and outcomes are in-
dependent from confounding factors, platelet function results are
never adjusted according to these at the bedside. Conversely,
adjusted analyses would be useful to project whether treatment
adjustments based on platelet reactivity could reduce bleeding or
ST; however, such adjustments are never perfect and cannot
account for all known confounders. Secondly, although there were
no meaningful interaction for outcomes between prasugrel and
clopidogrel-treated patients, the low number of prasugrel-treated
subjects may suggest that the associations between validated
cut-offs and outcomes might be relevant for clopidogrel but need
further confirmation for prasugrel. Moreover, any platelet function
assessment in ticagrelor-treated patients would not be capable to
measure possible pleiotropic effects of the drug, which might in
fact be the underlying cause of the observed reduction in mortality
risk in the PLATO trial.4 Finally, we admit that the pooled studies
were heterogeneous regarding the length of follow-up that may
introduce bias towards the exact determination of early-, and long-
term risk of ST and bleeding in relation to platelet reactivity levels
after PCI.
In conclusion, the present analysis shows in a large sample of
thienopyridine-treated patients that HPR, defined by validated
cut-offs using standardized platelet assays, is associated with a signifi-
cantly higher risk for ST and mortality, while LPR predicts a higher risk
for bleeding. The lowest rates of net adverse events in patients within
an intermediate range of platelet reactivity (OPR) suggest that plate-
let reactivity may be a valuable marker to discriminate between ST
and bleeding in patients after PCI. Further randomized trials are war-
ranted to test the potential benefit of tailoring treatment into the
optimal range of platelet reactivity.
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Supplementary material is available at European Heart Journal online.
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